Literature DB >> 33737722

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.

Christine Bekos1, Dietmar Pils2, Sabine Dekan3, Gerda Hofstetter3, Peter Horak4, Alexander Reinthaller1, Stephan Polterauer1, Richard Schwameis1, Stefanie Aust5.   

Abstract

The therapeutic potential of immune checkpoint inhibitors is currently being investigated in epithelial ovarian cancer (EOC), but immunological effects of the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis in EOC still remain poorly understood. The aim of this study was thus to compare infiltration rates of PD-1 and PD-L1 expressing tumor infiltrating leucocytes (TILs) in primary ovarian tumor tissue and metastatic intraperitoneal implants and to investigate its impact on overall survival (OS). Tumor specimens (ovarian tumor tissues and intraperitoneal metastases) of 111 patients were used to investigate the PD-1, PD-L1 and CD8 expression rates on TILs and PD-L1 expression rate of tumor cells. The percentages of CD8, PD-1, and PD-L1 expressing subpopulations of TILs differ in primary ovarian tumor tissues and metastatic intraperitoneal implants. High PD-1 among TILs in peritoneal metastases were associated with favorable OS. High PD-L1 expression in TILs was associated with poor OS. Combining both factors in peritoneal metastases revealed an unfavorable prognosis. Primary ovarian tumor tissue and intraperitoneal metastatic tissues in EOC might have different strategies to evade immune control. Those findings are of importance for the process of biomarker assessment to predict patients' response to immunotherapy.

Entities:  

Year:  2021        PMID: 33737722     DOI: 10.1038/s41598-021-85966-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Authors:  Mary L Disis; Matthew H Taylor; Karen Kelly; J Thaddeus Beck; Michael Gordon; Kathleen M Moore; Manish R Patel; Jorge Chaves; Haeseong Park; Alain C Mita; Erika P Hamilton; Christina M Annunziata; Hans Juergen Grote; Anja von Heydebreck; Jaspreet Grewal; Vikram Chand; James L Gulley
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

2.  Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Authors:  U A Matulonis; R Shapira-Frommer; A D Santin; A S Lisyanskaya; S Pignata; I Vergote; F Raspagliesi; G S Sonke; M Birrer; D M Provencher; J Sehouli; N Colombo; A González-Martín; A Oaknin; P B Ottevanger; V Rudaitis; K Katchar; H Wu; S Keefe; J Ruman; J A Ledermann
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

4.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Authors:  Naiyer A Rizvi; Julien Mazières; David Planchard; Thomas E Stinchcombe; Grace K Dy; Scott J Antonia; Leora Horn; Hervé Lena; Elisa Minenza; Bertrand Mennecier; Gregory A Otterson; Luis T Campos; David R Gandara; Benjamin P Levy; Suresh G Nair; Gérard Zalcman; Jürgen Wolf; Pierre-Jean Souquet; Editta Baldini; Federico Cappuzzo; Christos Chouaid; Afshin Dowlati; Rachel Sanborn; Ariel Lopez-Chavez; Christian Grohe; Rudolf M Huber; Christopher T Harbison; Christine Baudelet; Brian J Lestini; Suresh S Ramalingam
Journal:  Lancet Oncol       Date:  2015-02-20       Impact factor: 41.316

5.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.

Authors:  Brian Diskin; Salma Adam; Marcelo F Cassini; Gustavo Sanchez; Miguel Liria; Berk Aykut; Chandan Buttar; Eric Li; Belen Sundberg; Ruben D Salas; Ruonan Chen; Junjie Wang; Mirhee Kim; Mohammad Saad Farooq; Susanna Nguy; Carmine Fedele; Kwan Ho Tang; Ting Chen; Wei Wang; Mautin Hundeyin; Juan A Kochen Rossi; Emma Kurz; Muhammad Israr Ul Haq; Jason Karlen; Emma Kruger; Zennur Sekendiz; Dongling Wu; Sorin A A Shadaloey; Gillian Baptiste; Gregor Werba; Shanmugapriya Selvaraj; Cynthia Loomis; Kwok-Kin Wong; Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-03-09       Impact factor: 25.606

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.

Authors:  Katharina Auer; Anna Bachmayr-Heyda; Stefanie Aust; Nyamdelger Sukhbaatar; Agnes Teresa Reiner; Christoph Grimm; Reinhard Horvat; Robert Zeillinger; Dietmar Pils
Journal:  Oncotarget       Date:  2015-07-10

9.  Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer.

Authors:  Stefanie Aust; Sophie Felix; Katharina Auer; Anna Bachmayr-Heyda; Lukas Kenner; Sabine Dekan; Samuel M Meier; Christopher Gerner; Christoph Grimm; Dietmar Pils
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

10.  Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.

Authors:  Katharina Auer; Anna Bachmayr-Heyda; Nyamdelger Sukhbaatar; Stefanie Aust; Klaus G Schmetterer; Samuel M Meier; Christopher Gerner; Christoph Grimm; Reinhard Horvat; Dietmar Pils
Journal:  Oncotarget       Date:  2016-09-20
View more
  5 in total

Review 1.  Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.

Authors:  Yiru Long; Xiaolu Yu; Runqiu Chen; Yongliang Tong; Likun Gong
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

2.  Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response.

Authors:  Elise K Mann; Kevin J Lee; Dongquan Chen; Luciana Madeira da Silva; Valeria L Dal Zotto; Jennifer Scalici; Natalie R Gassman
Journal:  Biology (Basel)       Date:  2021-04-29

3.  Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients.

Authors:  Thomas Bartl; Arina Onoprienko; Gerda Hofstetter; Leonhard Müllauer; Nina Poetsch; Thorsten Fuereder; Paul Kofler; Stephan Polterauer; Christoph Grimm
Journal:  Biomolecules       Date:  2021-11-16

4.  Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-naïve patients: A single-center study.

Authors:  Ilias P Nikas; Cheol Lee; Min Ji Song; Bohyun Kim; Han Suk Ryu
Journal:  Cancer Med       Date:  2022-02-25       Impact factor: 4.711

5.  PD-L1 Expression in Different Segments and Histological Types of Ovarian Cancer According to Lymphocytic Infiltrate.

Authors:  Ljubiša Jovanović; Radmila Janković; Andja Ćirković; Milena Jović; Tijana Janjić; Slaviša Djuričić; Svetlana Milenković
Journal:  Medicina (Kaunas)       Date:  2021-11-29       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.